Incidence, clinical and biological associations of anti-CZP antibodies
| Disease | Dosage method | Patients (n) | CZP dose | Period (weeks) | ADAb (%) | Association with serum trough CZP level | Association with clinical response | Association with AEs | Association with MTX | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | NR | 126 | 400 mg/4 w | 24 | 5 (neutralising) | NR | NR | NR | NR | Choy et al102 |
| ELISA | 111 | 400 mg s.c./4 w month | 24 | 8.1 (neutralising) | NR | Negatively associated | NR | NR | Fleischmann et al103 | |
| NR | 492 | 400 mg at w0, 2 and 4 followed by 200 or 400 mg/2 w | 24 | 5.1 | NR | NR | NR | NR | Smolen et al104 | |
| ELISA | 982 | 400 mg at w0, 2 and 4 followed by 200 or 400 mg/2 w | 52 | 6.4 | NR | NR | NR | NR | Keystone et al11 | |
| Psoriasis | ELISA | 60 | 200 mg/2 w | 12 | 5 | NR | No | NR | NR | Reich et al105 |
| 57 | 400 mg/2 w | 4 | ||||||||
| 34 | 200 mg/2 w | 24 | 18 | |||||||
| 37 | 400 mg/2 w | 25 | ||||||||
| Crohn's disease | ELISA | 213 | 400 mg/4 w continuous group | 26 | 8 | Negatively associated | NR | No | NR | Lichtenstein et al106 |
| 209 | 400 mg/4 w drug-interruption group | 17.7 | ||||||||
| NR | 223 | 400 mg s.c. w0, 2 and 4 | 6 | 3.1 | NR | NR | NR | NR | Sandborn et al107 | |
| ELISA | 668 | 400 mg w0, 2 and 4 and then 4 w | 24 | 9 | NR | NR | NR | Inversely associated | Schreiber et al2 | |
| ELISA | 331 | 400 mg w0, 2 and 4 and then 4 w | 26 | 8 | NR | NR | NR | Inversely associated (AZA, MTX, mercaptopurine) | Sandborn et al108 |
ADAb, antidrug antibodies; AEs, adverse events; AZA, azathioprine; CZP, certolizumab pegol; MTX, methotrexate; NR, not reported; s.c., subcutaneous; w, week.